The Value of Immune-Related Genes Signature in Osteosarcoma Based on Weighted Gene Co-expression Network Analysis

被引:1
作者
Wang, Xin [1 ]
Gan, Li [2 ]
Ye, Ju [3 ]
Tang, Mengjie [4 ]
Liu, Wei [5 ]
机构
[1] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Bone & Soft Tissue,Xiangya Sch Med, Changsha 410013, Peoples R China
[2] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Anesthesiol,Xiangya Sch Med, Changsha 410013, Peoples R China
[3] Zunyi Med Univ, Dept Pharm, Zunyi 563000, Guizhou, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Pathol,Xiangya Sch Med, Changsha 410013, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Peoples R China
关键词
MODIFIED T-CELLS; NEUROFIBROMATOSIS TYPE-1; VARIABLE SELECTION; CANCER; IMMUNOTHERAPY; PROGRESSION; EXPRESSION; PROGNOSIS; TRIAL; INTRON;
D O I
10.1155/2021/9989321
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Osteosarcoma (OS) is a serious malignant tumor that is more common in adolescents or children under 20 years of age. This study is aimed at obtaining immune-related genes (IRGs) associated with the progression and prognosis of OS. Method. Expression profiling data and clinical data for OS were downloaded from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. ESTIMATE calculates immune scores and stromal scores of samples and performs the prognostic analysis. Weighted gene coexpression network analysis (WGCNA) was used to find modules correlated with immune and stromal scores. Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis were used to explore IRGs associated with OS prognosis and construct and validate a hazard score model. Finally, we verified the expression and function of EVI2B in OS. Results. WGCNA selected twenty-eight IRGs, 10 of which were associated with OS prognosis, and LASSO further obtained three key prognostic genes. A prognostic model of EVI2B was constructed, and according to the risk score model, patients in the high-risk group had a worse prognosis than those in the low-risk group, and the prognosis was statistically significant in the high- and low-risk groups. Receiver operating characteristic (ROC) curves were used to assess the prognostic model's accuracy and externally validate the independent GSE21257 cohort. The results of immunohistochemical staining and qPCR showed that EVI2B was a tumor suppressor gene. The differential genes in the high- and low-risk groups were analyzed by enrichment analysis of GO and KEGG, indicating that the EVI2B model is associated with immune response. Conclusion. In this study, IRG EVI2B is closely related to OS's prognosis and can be used as a potential biomarker for prognosis and treatment of OS.
引用
收藏
页数:17
相关论文
共 72 条
[1]   Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion [J].
Aalto, Y ;
El-Rifai, W ;
Vilpo, L ;
Ollila, J ;
Nagy, B ;
Vihinen, M ;
Vilpo, J ;
Knuutila, S .
LEUKEMIA, 2001, 15 (11) :1721-1728
[2]   Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].
Ahmed, Nabil ;
Brawley, Vita S. ;
Hegde, Meenakshi ;
Robertson, Catherine ;
Ghazi, Alexia ;
Gerken, Claudia ;
Liu, Enli ;
Dakhova, Olga ;
Ashoori, Aidin ;
Corder, Amanda ;
Gray, Tara ;
Wu, Meng-Fen ;
Liu, Hao ;
Hicks, John ;
Rainusso, Nino ;
Dotti, Gianpietro ;
Mei, Zhuyong ;
Grilley, Bambi ;
Gee, Adrian ;
Rooney, Cliona M. ;
Brenner, Malcolm K. ;
Heslop, Helen E. ;
Wels, Winfried S. ;
Wang, Lisa L. ;
Anderson, Peter ;
Gottschalk, Stephen .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+
[3]   Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression [J].
Ahmed, Nabil ;
Salsman, Vita S. ;
Yvon, Eric ;
Louis, Chrystal U. ;
Perlaky, Laszlo ;
Wels, Winfried S. ;
Dishop, Meghan K. ;
Kleinerman, Eugenie E. ;
Pule, Martin ;
Rooney, Cliona M. ;
Heslop, Helen E. ;
Gottschalk, Stephen .
MOLECULAR THERAPY, 2009, 17 (10) :1779-1787
[4]  
Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
[5]   Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature [J].
Andreopoulos, Bill ;
Anastassiou, Dimitris .
CANCER INFORMATICS, 2012, 11 :61-75
[6]   Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy [J].
Angulo, Pablo ;
Kaushik, Gaurav ;
Subramaniam, Dharmalingam ;
Dandawate, Prasad ;
Neville, Kathleen ;
Chastain, Katherine ;
Anant, Shrikant .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
[7]   Gene Ontology: tool for the unification of biology [J].
Ashburner, M ;
Ball, CA ;
Blake, JA ;
Botstein, D ;
Butler, H ;
Cherry, JM ;
Davis, AP ;
Dolinski, K ;
Dwight, SS ;
Eppig, JT ;
Harris, MA ;
Hill, DP ;
Issel-Tarver, L ;
Kasarskis, A ;
Lewis, S ;
Matese, JC ;
Richardson, JE ;
Ringwald, M ;
Rubin, GM ;
Sherlock, G .
NATURE GENETICS, 2000, 25 (01) :25-29
[8]   Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study [J].
Bagnoli, Marina ;
Canevari, Silvana ;
Califano, Daniela ;
Losito, Simona ;
Di Maio, Massimo ;
Raspagliesi, Francesco ;
Carcangiu, Maria Luisa ;
Toffoli, Giuseppe ;
Cecchin, Erika ;
Sorio, Roberto ;
Canzonieri, Vincenzo ;
Russo, Daniela ;
Scognamiglio, Giosue ;
Chiappetta, Gennaro ;
Baldassarre, Gustavo ;
Lorusso, Domenica ;
Scambia, Giovanni ;
Zannoni, Gian Franco ;
Savarese, Antonella ;
Carosi, Mariantonia ;
Scollo, Paolo ;
Breda, Enrico ;
Murgia, Viviana ;
Perrone, Francesco ;
Pignata, Sandro ;
De Cecco, Loris ;
Mezzanzanica, Delia .
LANCET ONCOLOGY, 2016, 17 (08) :1137-1146
[9]   Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma [J].
Bernthal, Nicholas M. ;
Federman, Noah ;
Eilber, Frederick R. ;
Nelson, Scott D. ;
Eckardt, Jeffrey J. ;
Eilber, Fritz C. ;
Tap, William D. .
CANCER, 2012, 118 (23) :5888-5893
[10]  
Bielack Stefan S, 2016, F1000Res, V5, P2767